- Home
- FINS vs HELP Comparison
FINS vs HELP Comparison
Compare FINS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINS | HELP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.4M | 366.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | FINS | HELP |
|---|---|---|
| Price | $13.09 | $7.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 56.3K | ★ 579.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.21 | $5.76 |
| 52 Week High | $13.64 | $8.23 |
Technical Indicators
Market Signals| Indicator | FINS | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 62.79 |
| Support Level | $13.06 | $7.33 |
| Resistance Level | $13.24 | $8.23 |
| Average True Range (ATR) | 0.09 | 0.62 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 32.50 | 95.50 |
Price Performance
Historical ComparisonAbout FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.